|
| 36318705 | Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. | Clin Cancer Res | 2023 |
| 37708629 | Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. | Eur J Cancer | 2023 |
| 37494316 | Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey. | Can Urol Assoc J | 2023 |
| 36952634 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37322621 | Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial. | Asian J Androl | 2023 |
| 37289025 | The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. | Cancer Res | 2023 |
| 36948922 | Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2023 |
| 36990608 | Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 37040594 | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37404070 | Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. | J Manag Care Spec Pharm | 2023 |
| 37269841 | Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37399894 | Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. | Ann Oncol | 2023 |
| 36994854 | Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results. | Oncologist | 2023 |
| 36858151 | Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. | Ann Oncol | 2023 |
| 36697317 | Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. | Clin Genitourin Cancer | 2023 |
| 36914848 | A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. | NPJ Precis Oncol | 2023 |
| 36932416 | Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy. | Cancer Imaging | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36043882 | Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. | Clin Cancer Res | 2023 |
| 36222898 | Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer. | J Cancer Res Clin Oncol | 2023 |
| 34259202 | Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial. | Asian J Androl | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35579584 | Update on metastatic hormone-sensitive prostate cancer. | Clin Adv Hematol Oncol | 2022 |
| 35366072 | Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. | Cancer Chemother Pharmacol | 2022 |
| 35568679 | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. | Eur J Cancer | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35859180 | Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. | Nature | 2022 |
| 36656694 | 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text. | Can Urol Assoc J | 2022 |
| 36439451 | Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation. | Front Oncol | 2022 |
| 36309516 | The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. | Nat Commun | 2022 |
| 36176410 | Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. | Front Oncol | 2022 |
| 36332173 | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. | JCO Glob Oncol | 2022 |
| 36166584 | TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors. | Oncologist | 2022 |
| 36378572 | 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). | Can Urol Assoc J | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 34953443 | Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. | Eur J Cancer | 2022 |
| 35131040 | Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 34965947 | The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. | Clin Cancer Res | 2022 |
| 34928708 | Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. | J Clin Oncol | 2022 |
| 35293030 | Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study. | Int J Urol | 2022 |
| 34812730 | Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. | Can Urol Assoc J | 2022 |
| 34843005 | A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. | Invest New Drugs | 2022 |
| 32853135 | Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. | Can Urol Assoc J | 2021 |
| 33769071 | Olaparib for the treatment of metastatic prostate cancer. | Future Oncol | 2021 |
| 33754187 | Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). | Cancer Chemother Pharmacol | 2021 |
| 33836265 | Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. | Ann Oncol | 2021 |
| 33556313 | 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). | Can Urol Assoc J | 2021 |
| 33690902 | Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. | Cancer | 2021 |
| 33914595 | Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. | J Clin Oncol | 2021 |